News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Withdraws Nod to 27 Ranbaxy Laboratories (RANBAXY.BO) ANDAs


8/23/2012 6:27:21 AM

The US Food and Drug Administration has withdrawn approval given to 27 generic products of Ranbaxy Laboratories. In a letter posted on its website, the regulator said Ranbaxy had requested for withdrawal of approval to 27 of its abbreviated new drug applications (ANDAs) under a consent decree it entered in January this year. The 27 drugs include certain antibiotic capsules and oral suspensions, and drugs for fungal infection and diabetes. A Ranbaxy spokesperson said these products do not pertain to the current business of the company and hence will have negligible impact.

Read at DNA India
Read at EconomicTimes
Read at Business Standard
Read at Hindustan Times
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES